JP2023513605A5 - - Google Patents
Info
- Publication number
- JP2023513605A5 JP2023513605A5 JP2022549103A JP2022549103A JP2023513605A5 JP 2023513605 A5 JP2023513605 A5 JP 2023513605A5 JP 2022549103 A JP2022549103 A JP 2022549103A JP 2022549103 A JP2022549103 A JP 2022549103A JP 2023513605 A5 JP2023513605 A5 JP 2023513605A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062976654P | 2020-02-14 | 2020-02-14 | |
| US62/976,654 | 2020-02-14 | ||
| PCT/US2021/017958 WO2021163562A2 (en) | 2020-02-14 | 2021-02-12 | Compositions and methods comprising splicing-derived antigens for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023513605A JP2023513605A (ja) | 2023-03-31 |
| JPWO2021163562A5 JPWO2021163562A5 (https=) | 2024-02-16 |
| JP2023513605A5 true JP2023513605A5 (https=) | 2024-02-16 |
Family
ID=77295208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022549103A Pending JP2023513605A (ja) | 2020-02-14 | 2021-02-12 | がんを処置するためのスプライシング由来抗原を含む組成物および方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240182518A1 (https=) |
| EP (1) | EP4103738A4 (https=) |
| JP (1) | JP2023513605A (https=) |
| CN (1) | CN115485395A (https=) |
| WO (1) | WO2021163562A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4055182A4 (en) * | 2019-11-08 | 2024-07-03 | The Regents Of The University Of California | IDENTIFICATION OF SPLICE-DRIVEN ANTIGENS FOR CANCER TREATMENT |
| US20250352576A1 (en) * | 2022-04-01 | 2025-11-20 | The Regents Of The University Of California | Methods and compositions for treating gliomas |
| CN116178567B (zh) * | 2022-10-28 | 2025-01-28 | 四川大学华西医院 | 一种靶向TGFβRII的嵌合抗原受体及其用途 |
| EP4695284A1 (en) * | 2023-04-11 | 2026-02-18 | The Regents of University of California | Human t cell receptors targeting tumor-enhanced splicing epitopes on hla-a*02:01 for small cell carcinoma |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6436703B1 (en) * | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| US8021658B2 (en) * | 2001-05-25 | 2011-09-20 | Thomas Jefferson University | Alternative splice forms of proteins as basis for multiple therapeutic modalities |
| EP4012714A1 (en) * | 2010-03-23 | 2022-06-15 | Iogenetics, LLC. | Bioinformatic processes for determination of peptide binding |
| GB201602918D0 (en) * | 2016-02-19 | 2016-04-06 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
| US20180305776A1 (en) * | 2017-04-20 | 2018-10-25 | The Board Of Trustees Of The Leland Stanford Junior University | Myc-reporters, cells containing myc-reporters and methods of use thereof |
| EP4055182A4 (en) * | 2019-11-08 | 2024-07-03 | The Regents Of The University Of California | IDENTIFICATION OF SPLICE-DRIVEN ANTIGENS FOR CANCER TREATMENT |
-
2021
- 2021-02-12 JP JP2022549103A patent/JP2023513605A/ja active Pending
- 2021-02-12 US US17/760,479 patent/US20240182518A1/en active Pending
- 2021-02-12 CN CN202180028467.5A patent/CN115485395A/zh active Pending
- 2021-02-12 EP EP21754447.7A patent/EP4103738A4/en not_active Withdrawn
- 2021-02-12 WO PCT/US2021/017958 patent/WO2021163562A2/en not_active Ceased